LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

ABBV

225.16

+3.14%↑

UNH

327.41

+1.82%↑

AZN

89.05

+1.79%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

200.84 2.51

Buy Sell

Overview

Share price change

24h

Current

Min

192.23

Max

202.3

Key metrics
By Trading Economics
Income	56M -39M
Sales	57M 158M
Profit margin	-24.585
Employees	1,017
EBITDA	51M 2.3M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+30.79% upside

Dividends
By Dow Jones
Next Earnings	12 lis 2025

Market Stats
By TradingEconomics
Market Cap	1B 12B
Previous open	198.33
Previous close	200.84

News Sentiment

By Acuity

50%

180 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lis 2025, 23:59 UTC

Earnings

Singtel's 1st Half Net Profit Surges

11 lis 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 lis 2025, 22:21 UTC

Earnings

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 lis 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 lis 2025, 23:44 UTC

Earnings

Singtel's 1H Net Profit Surges

11 lis 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 lis 2025, 23:18 UTC

Earnings

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 lis 2025, 23:15 UTC

Earnings

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 lis 2025, 23:14 UTC

Earnings

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 lis 2025, 23:12 UTC

Earnings

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 lis 2025, 23:11 UTC

Earnings

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 lis 2025, 23:10 UTC

Earnings

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 lis 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 lis 2025, 21:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

11 lis 2025, 21:46 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 lis 2025, 21:41 UTC

Earnings

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 lis 2025, 21:40 UTC

Earnings

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 lis 2025, 21:39 UTC

Earnings

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 lis 2025, 21:38 UTC

Earnings

Aristocrat: Final Dividend 49 Australian Cents/Share

11 lis 2025, 21:37 UTC

Earnings

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 lis 2025, 21:36 UTC

Earnings

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 lis 2025, 21:35 UTC

Earnings

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Adj EPS 79c >ALC

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q Rev $2.61B >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 lis 2025, 21:35 UTC

Earnings

Alcon 3Q EPS 48c >ALC.EB

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

30.79% upside

12 Months Forecast

Average 256.36 USD 30.79%

High 307 USD

Low 220 USD

Based on 11 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

180 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.